Harvard Bioscience (HBIO) Projected to Post Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIO) is anticipated to announce its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.62) per share and revenue of $21.20 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.

Harvard Bioscience Price Performance

Shares of NASDAQ:HBIO traded up $0.14 on Tuesday, hitting $6.54. The stock had a trading volume of 2,089 shares, compared to its average volume of 51,326. The firm’s 50 day moving average price is $5.57 and its 200-day moving average price is $5.90. The company has a debt-to-equity ratio of 2.61, a quick ratio of 1.25 and a current ratio of 2.20. Harvard Bioscience has a twelve month low of $2.81 and a twelve month high of $9.50. The company has a market capitalization of $29.51 million, a price-to-earnings ratio of -0.51 and a beta of 1.57.

Insiders Place Their Bets

In related news, Director Stephen J. Denelsky acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was purchased at an average price of $4.87 per share, for a total transaction of $48,700.00. Following the transaction, the director directly owned 21,000 shares of the company’s stock, valued at approximately $102,270. This trade represents a 90.91% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William Snider acquired 12,525 shares of Harvard Bioscience stock in a transaction on Monday, March 16th. The shares were purchased at an average cost of $4.99 per share, for a total transaction of $62,499.75. Following the acquisition, the director owned 23,525 shares in the company, valued at approximately $117,389.75. This represents a 113.86% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders purchased 36,000 shares of company stock valued at $177,354. Insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Harvard Bioscience

Several hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in Harvard Bioscience during the 4th quarter worth about $40,000. XTX Topco Ltd acquired a new position in Harvard Bioscience during the 4th quarter valued at about $26,000. Corsair Capital Management L.P. boosted its stake in shares of Harvard Bioscience by 1,008.7% in the 4th quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock valued at $741,000 after purchasing an additional 1,008,692 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Harvard Bioscience during the 4th quarter worth approximately $124,000. Finally, Renaissance Technologies LLC grew its position in shares of Harvard Bioscience by 17.6% during the 4th quarter. Renaissance Technologies LLC now owns 1,021,241 shares of the medical instruments supplier’s stock worth $683,000 after buying an additional 152,763 shares during the period. Institutional investors own 80.87% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HBIO. Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Friday, March 27th. New Street Research set a $6.00 target price on shares of Harvard Bioscience in a research note on Friday, March 13th. Wall Street Zen lowered Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Benchmark cut their price objective on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating for the company in a research report on Friday, March 13th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $6.00.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.